Therapy of Hepatocellular Carcinoma with Iodine-131-Lipidiol

Ahmadzadehfar, Hojjat; Sabet, Amir; Biersack, H.-J.; Risse, J. H.

doi:10.5772/28626

Cited by 2 publications

(4 citation statements)

References 56 publications

(55 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Second, techniques using 90 Y-labeled products tend to cost up to 10 times more than therapy with 131 I-Lipiodol. [3] Third, Iodine is an integral constituent of lipiodol, hence 131 I–lipiodol which is produced by isotopic exchange and the radioisotope remains a stable constituent of the lipiodol, limiting leaching and unintended systemic therapy; in contrast, early 90 Y devices had high rates of leaching of 90 Y from the compounds, resulting in significant bone marrow toxicity.…”

Section: Discussionmentioning

confidence: 99%

“…Advantages of 131 I-Lipiodol over 90 Y are cost effectiveness, selective cytotoxicity for the tumor cells, inability of tumor cells to expel Lipiodol further enhancing its cytotoxic effect and long half-life of 8 days. [3]…”

Section: Discussionmentioning

confidence: 99%

“…Although 90 Y radioembolization is currently the preferred method for treating liver metastases compared to Iodine-131 ( 131 I)-Lipiodol, it has few disadvantages. [3] Most of the published data on TARE in hepatic metastases is based on 90 Y microspheres with limited studies using 131 I-Lipiodol. The available studies on TARE with 131 I-Lipiodol are on small sample size, stressing the need for a more elaborate study on its use in hepatic metastases.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Transarterial radioembolization with Iodine-131-Lipiodol for hepatic metastases from gastrointestinal malignancies – Experience in tertiary care oncology center in India

Bhargavi

Subbanna

Kallur

et al. 2019

South Asian J Cancer

View full text Add to dashboard Cite

Context:Unresectable colorectal hepatic metastases can be treated with radioembolization.Aims:The aim of this study is to analyze the response and survival benefits of transarterial radioembolization (TARE) with Iodine-131 (131I) Lipiodol for hepatic metastases from gastrointestinal malignancies.Settings and Design:Retrospective study of 20 patients with pathologically proven hepatic metastases from primary gastrointestinal malignancies referred for palliative therapy with TARE.Subjects and Methods:At baseline, standard laboratory and imaging data were recorded. All patients fulfilling the inclusion/exclusion criteria underwent TARE with 131I Lipiodol. Post procedure, the patients were reviewed after 1 month with follow-up positron emission tomography–computed tomography and tumor marker levels to evaluate treatment response with continued follow-up till December 2016 and overall survival calculated.Statistical Analysis Used:Data were analyzed using a statistical analysis package (Social sciences, version 15.0 for Windows; SSPS Inc.). Survival data were plotted using Kaplan–Meier survival curves.Results:At the end of follow-up period, 15 of 20 patients were alive. The mean and median survival was 38.88 ± 5.0 months (95% confidence interval [CI], 29.03–48.74 months, P = 0.17) and 49.3 ± 12.4 months (95% CI, 25.0–73.7 months, P = 0.17), respectively. 66 months survival was 75%. Response evaluation in 10 patients showed partial response in 3 (30%), stable disease in 2 (20%) and progressive disease in 5 (50%) patients. All patients with partial response showed a reduction in serum tumor marker levels.Conclusions:TARE with 131I-Lipiodol is highly effective with a significant survival benefit in refractory cases of hepatic metastases from gastrointestinal malignancies.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Transarterial radioembolization with Iodine-131-Lipiodol for hepatic metastases from gastrointestinal malignancies – Experience in tertiary care oncology center in India

Bhargavi

Subbanna

Kallur

et al. 2019

South Asian J Cancer

View full text Add to dashboard Cite

show abstract

“…The only routinely used α-emitter for the treatment of metastatic disease is Radium-223 ( 223 Ra), which has been approved for the treatment of bone metastases in patients with prostate cancer and symptomatic disease with no known visceral metastases [10]. The physical half-life of therapeutic radionuclide is an important consideration and an underlying principle for therapy planning [11].…”

Section: Introductionmentioning

confidence: 99%

Targeted Therapy for Metastatic Prostate Cancer with Radionuclides

Ahmadzadehfar¹

2016

Prostate Cancer - Leading-Edge Diagnostic Procedures and Treatments

Self Cite

View full text Add to dashboard Cite

Progression to androgen-independent status is the main cause of death in patients with metastatic prostate cancer. Prostate-specific membrane antigen PSMA is anchored in the cell membrane of prostate epithelial cells. PSMA is highly expressed on prostate epithelial cells and strongly upregulated in prostate cancer. Therefore, it is an appropriate target for diagnosis and therapy of prostate cancer and its metastases. There is growing knowledge about promising response and low toxicity profile of radioligand therapy of metastatic castration-resistant prostate cancer using Lutetium--labeled PSMA ligands. For patients with only bone metastases, there are different radionuclides which have been used for decades. In this chapter, different methods of targeted radionuclide therapy of metastatic prostate cancer are described.Keywords: PSMA, prostate cancer, radioligand therapy, metastatic disease, PSA, bone metastasis, radionuclide therapy . IntroductionAlmost all patients with metastatic prostate cancer PC will initially respond to well-established and innovative anti-androgen treatments including the two recently approved hormone therapy agents, enzalutamide and abiraterone [ , ], which significantly improve overall survival. However, progression to androgen-independent status is the main cause of death in these patients [ ]. Most deaths related to PC are due to metastatic disease, which results from any combination of blood, lymphatic, or local spread. Targeted radionuclide therapy is an attractive and quickly developing therapy option for many different cancers, such as lymphoma, melanoma, and neuroendocrine tumors [ -]. Radionuclide therapies should be © 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.targeted, because this procedure always involves the administration of unsealed sources of radioactivity.Most therapeutic tracers utilize -particle emissions due to the ability of these particles to penetrate tissues. The deposition of energy in tissue by -emitters results in cellular damage. Among the -emitters, there are several choices regarding the energy of the -emission. Lower energy -particles can travel a few cell diameters, or at most in the submillimeter range. Higher energy -particles, such as those emitted by Yttrium-Y or LutetiumLu , have excellent tissue penetration with a range beyond the source of several millimeters [ , ]. The only routinely used -emitter for the treatment of metastatic disease is RadiumRa , which has been approved for the treatment of bone metastases in patients with prostate cancer and symptomatic disease with no known visceral metastases [ ]. The physical half-life of therapeutic radionuclide is an important consideration and an underlying principle for therapy planning [ ].. PSMA as a targetProstate-specific membrane antigen PSMA ...

show abstract

Therapy of Hepatocellular Carcinoma with Iodine-131-Lipidiol

Cited by 2 publications

References 56 publications

Transarterial radioembolization with Iodine-131-Lipiodol for hepatic metastases from gastrointestinal malignancies – Experience in tertiary care oncology center in India

Transarterial radioembolization with Iodine-131-Lipiodol for hepatic metastases from gastrointestinal malignancies – Experience in tertiary care oncology center in India

Targeted Therapy for Metastatic Prostate Cancer with Radionuclides

Contact Info

Product

Resources

About